Evidence map›Paper›PMID 28738061›Full record

ArticlePloS one2017

Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Michel Modo, William R Crum, Madeline Gerwig, Anthony C Vernon, Priya Patel, Michael J Jackson, Sarah Rose, Peter Jenner, Mahmoud M Iravani

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Michel ModoDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.ORCID http://orcid.org/0000-0003-4436-735X
William R CrumDepartment of Neuroimaging, King's College London, London, United Kingdom.
Madeline GerwigDepartment of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Anthony C VernonDepartment of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.
Priya PatelDepartment of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.
Michael J JacksonInstitute of Pharmaceutical Sciences, King's College London, London, United Kingdom.
Sarah RoseInstitute of Pharmaceutical Sciences, King's College London, London, United Kingdom.
Peter JennerInstitute of Pharmaceutical Sciences, King's College London, London, United Kingdom.
Mahmoud M IravaniInstitute of Pharmaceutical Sciences, King's College London, London, United Kingdom.
King's College London · GBUniversity of Pittsburgh · USUniversity of Hertfordshire · GB

Funding

Medical Research Council MR/N026063/1
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder producing a variety of motor and cognitive deficits with the causes remaining largely unknown. The gradual loss of the nigrostriatal pathway is currently considered the pivotal pathological event. To better understand the progression of PD and improve treatment management, defining the disease on a structural basis and expanding brain analysis to extra-nigral structures is indispensable. The anatomical complexity and the presence of neuromelanin, make the use of non-human primates an essential element in developing putative imaging biomarkers of PD. To this end, ex vivo T2-weighted magnetic resonance images were acquired from control and 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated marmosets. Volume measurements of the caudate, putamen, and substantia nigra indicated significant atrophy and cortical thinning. Tensor-based morphometry provided a more extensive and hypothesis free assessment of widespread changes caused by the toxin insult to the brain, especially highlighting regional cortical atrophy. The results highlight the importance of developing imaging biomarkers of PD in non-human primate models considering their distinct neuroanatomy. It is essential to further develop these biomarkers in vivo to provide non-invasive tools to detect pre-symptomatic PD and to monitor potential disease altering therapeutics.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsBehavior, AnimalBiomarkersCallithrixDisease Models, AnimalFemaleMagnetic Resonance ImagingMaleMPTP PoisoningParkinson DiseaseSubstantia Nigra1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineBiomarkers

Identifiers

PMID28738061
PMCPMC5524324
OpenAlexW2736812595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.